枯草杆菌、肠球菌二联活菌肠溶胶囊治疗溃疡性结肠炎的疗效分析

Bacillus subtilis and enterococcus double viable capsules in treatment of ulcerative colitis

目的探讨枯草杆菌、肠球菌二联活菌肠溶胶囊治疗溃疡性结肠炎的效果。方法收集本院2014年1月至2015年6月收治的100例溃疡性结肠炎患者，随机分为对照组与实验组。对照组给予美沙拉嚷治疗，实验组加服枯草杆菌、肠球菌二联活菌肠溶胶囊，比较两组整体治疗效果、复发率、缓解与维持时间、ESR、CRP与不良反应。结果实验组治疗总有效率（94％）与维持时间[（0．69±0．24）年]显著高于对照组[74％，（0．51±0．16）年]，缓解时间[（50．14±9．15）d]显著低于对照组[（57．47±9．84）d]，差异有统计学意义（x2=7．440，t=3．922、3．857，P〈0．01）；实验组治疗后ESR[（14．71±7．04）mm／h]与CRP水平[（10．15±3．53）mg/L]显著低于对照组[（20．15±8．25）mm／h，（19．53±4．39）mg／L]，差异有统计学意义（t=3．547、11．774，P〈n01），复发率（14％）明显低于对照组（32％），差异有统计学意义（x2=4．534，P〈0．05）；两组总体不良反应发生率差异无统计学意义（16％VS．10％，Y。=0．796，P〉0．05）。结论枯草杆菌、肠球菌二联活菌肠溶胶囊治疗溃疡性结肠炎的疗效显著，且安全性较高，具有借鉴性。

Objective To investigate the effect of bacillus subtilis and enterococcus double viable capsules in the treatment of ulcerative colitis. Methods 100 patients with ulcerative colitis admitted into our hospital from January, 2014 to June, 2015 were randomly divided into a control group and an experimental group. The control group were treated with mesalazine and in addition the experimental group with bacillus subtilis and enterococcus double viable capsules. The overall curative effect, recurrence rate, remission and maintenance times, ESR, CRP, and adverse reactions were compared between these two groups. Results The overall response rate, maintenance time, and remission time were 94%, （0.69 ±0.24） year, （50.14±9.15） d in the experimental group and were 74%, （0.51 ± 0.16） year, and （57.47 ± 9.84） d in the control group, with statistical differences （X 2=7.440, t=3.922, 3.857, P〈0.01）. After the treatment, the ESR, CRP level, recurrence rate were significantly lower in the experimental group than in the control group [ （14.71±7.04） mm/h vs. （20.15 ±8.25） mm/h, （10.15 ± 3.53） rag/ L vs. （19.53 ±4.39） mm/h, and 14% vs. 32%], with statistical differences （t=-3.547,11.774, P〈0.01;X 2=4.534, P〈0.05）. There was no statistical difference in the incidence of adverse reactions between these two groups （16% vs. 10%, X 2=0.796, P〉0.05）. Conclusions Bacillus subtilis and enterococcus double viable capsules in the treatment of ulcerative colitis is effective and safe and is of reference.